Category Archives: Indian Patent Law

A Matter of Life and Death

Source: Inter Press Service 13 March 2014 Martin Khor, executive director of the South Centre, warns that negotiations on the Trans Pacific Partnership Agreement are a matter of life and death. GENEVA, Mar 9 2014 (IPS) – If you or … Continue reading

Posted in access to medicines, Indian Patent Law, patent, TPPA, Trans-Pacific Partnership Agreement | Leave a comment

A flimsy case against Indian pharma

Source: Business Line 10 March 2014 Trade tensions between the US and India are on the rise. Multiple trade organisations have asked the US Trade Representative to designate India a Priority Foreign Country in its annual review of countries that … Continue reading

Posted in access to medicines, Compulsory Licensing, Indian Patent Law, Novartis Case, patent evergreening, Sec 3 (d), TRIPS, TRIPS flexibilities, US pressure on India | Leave a comment

India hardens trade stance against US, wants disputes to go to WTO

Source: Times of India 26 Feb 2014 NEW DELHI: The government is set to ask all its officials to stay away from any interaction with a delegation from the US International Trade Commission (USITC), a quasi-judicial agency, probing the impact … Continue reading

Posted in Indian Patent Law, IP Rights, patent, patent evergreening, Patent Opposition, US pressure on India | Leave a comment

Novartis puts pressure on India over patent abuse

Source: Financial Times 24 Feb 2014 Novartis has urged US and European governments to “apply pressure” on India to respect intellectual property and warned New Delhi that its stance on patents is deterring investment. Joe Jimenez, chief executive of the Swiss drugmaker, … Continue reading

Posted in Indian Patent Law, patent evergreening, Sec 3 (d), Uncategorized | Leave a comment

Battles Over Patents: Is India Changing The Rules Of The Game?

Source: Intellectual Property Watch 21 Feb 2014 Over the last couple of years, news of pharmaceutical patents and India’s attempts to protect and manage its market has caught the attention of intellectual property observers everywhere and the pharmaceutical industry in … Continue reading

Posted in Compulsory Licensing, Indian Patent Law, patent evergreening, Patent Opposition, Revocation | Tagged , | Leave a comment

Indian firms under pressure on drug patent regime, as global majors mount lobbying

Source: Hindustan Times 21 Feb 2014 India is defending its patent regime more aggressively than ever before from attacks in the US that have come to define the state of ties between the two countries lately. The first sign of … Continue reading

Posted in Compulsory Licensing, Indian Patent Law, patent evergreening, Patent Opposition, Revocation | Tagged , | Leave a comment

Comments Posted for ‘Special 301′ Review of Foreign Nations’ Intellectual Property Policies: Rightholders Focus on India

Source: Info Justice 11 Feb 2014 Last Friday, an interagency committee led by the U.S. Trade Representative received comments for the 2014 Special 301 Review.  This annual review is a process in which it identifies countries that allegedly “deny adequate … Continue reading

Posted in Compulsory Licensing, Indian Patent Law, IP Rights, Special 301 report | Leave a comment

US Chamber of Commerce’s International Intellectual Property Index 2014 says India is is worst in the world in protecting patents!!

Source: Business Standard, 30 Jan 2014 Protecting patents: India worst in world Ranking by arm of US Chamber of Commerce; study says all BRICS countries lack the required drive to enforce patents; Indian law & SC rulings rapped Despite the … Continue reading

Posted in Compulsory Licensing, Indian Patent Law, IPR Enforcement, Revocation | Leave a comment

Bayer’s CEO calls Sorafenib (cancer drug) Compulsory Licence in India as essential theft

21 Jan 2014 Source: Bloomberg Newsweek In a news report by Bloomberg Bayer’s CEO Marjin Dekker was quoted saying” We did not develop this medicine for Indians,” Dekkers said Dec. 3. “We developed it for western patients who can afford it.” … Continue reading

Posted in Compulsory Licensing, Indian Patent Law | Leave a comment

Chennai Patent Office revokes Pfizer’s second patent on Detrol

Source: Pharmabiz 24 Dec 2013 In yet another blow to the multinational drug companies in patent cases in India, the Chennai Patent Office has revoked Pfizer’s patent on Detrol, a drug used to manage overactive bladder symptoms. The patent on … Continue reading

Posted in Indian Patent Law, patent evergreening, Patent Opposition | Leave a comment